FDA enlists doctors to help spot misleading drug advertisementsBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c2594 (Published 14 May 2010) Cite this as: BMJ 2010;340:c2594
- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration has launched a programme called “Bad Ad” to enlist doctors in reporting false or misleading drug advertising or promotions.
Drug company advertising, promotional materials, presentations at medical meetings, and presentations to individual doctors by sales representatives are supposed to be accurate and balanced. They should present the risks and the benefits of a drug, and they should not promote a drug for unapproved, or “off label,” uses.
The FDA, however, has only a few dozen staff members to review hundreds of drug advertisements, brochures, and presentations that companies voluntarily …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial